Status Epilepticus (SE) is an important neurological emergency defined as seizures lasting for 5 minutes or more or recurrent seizures without recovery of consciousness to baseline between the attacks. The causes of SE vary; including stroke, infections, trauma and metabolic disorders. In children, fevers also are a causal factor.
Refractory Status Epilepticus (RSE) is defined as SE persisting despite sufficient dose of benzodiazepines and at least one antiepileptic drug (AED), irrespective of time. RSE is associated with acute, severe, and potentially fatal underlying etiologies such as encephalitis, massive stroke, or rapidly progressive primary brain tumors, and may be accompanied by severe impairment of consciousness.
In general, RSE occurs in patients with new-onset seizures rather than in patients with chronic epilepsy. The etiology of RSE in developing countries is dominated by central nervous system (CNS) infections and head injury compared to stroke and drug withdrawal in the developed countries.
The Refractory status epilepticus market report covers emerging drugs, current treatment practices, Refractory status epilepticus market share of the individual therapies, current and forecasted Refractory status epilepticus Market Size from 2017 to 2030 segmented by seven major markets.
The report also provides detailed current Refractory status epilepticus treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Refractory status epilepticus Market Key Facts
Status epilepticus (SE) is a common medical emergency associated with high morbidity and mortality. Mortality from SE varies from 3–50% in different studies. In elderly patients, refractory status epilepticus (RSE) may lead to death in over 76% cases.
According to the review of literature, Refractory Status Epilepticus occurs in 29 – 43% of SE cases (Novy et al.) A recent article by Leitinger et al. reporting SE frequency of 36.1/100,000.
In one study of 395 patients with refractory Status Epilepticus treated in the ICU, the prevalence was found to be 3.4 per 100,000. (Kantanen al.) In a study, Status Epilepticus (SE) is reported with annual cases to be 10–40/100,000 (Coeytaux et al.)
Visit For Sample Pages:
Key Benefits of Refractory status epilepticus Market Report
Refractory status epilepticus market report provides an in-depth analysis of Refractory status epilepticus Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Refractory status epilepticus market report will help in developing business strategies by understanding the Refractory status epilepticus Market trends & developments, key players and future market competition that will shape and drive the Refractory status epilepticus market in the upcoming years.
The Refractory status epilepticus market report covers Refractory status epilepticus current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Refractory status epilepticus market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Refractory status epilepticus Market
The Refractory status epilepticus market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Refractory status epilepticus market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Refractory status epilepticus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Refractory status epilepticus Epidemiology
The Refractory status epilepticus epidemiology section covers insights about historical and current Refractory status epilepticus patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Refractory status epilepticus Drugs Uptake and Key Market Players
The Refractory status epilepticus Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Refractory status epilepticus market or expected to get launched in the market during the study period. The analysis covers Refractory status epilepticus market uptake by drugs; patient uptake by therapies; and sales of each drug.
Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Refractory status epilepticus (RSE) market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Key players, such as Marinus Pharma, Sage Therapeutics and others. are involved in developing drugs for Refractory status epilepticus (RSE).
Some of the emerging therapies in the Refractory status epilepticus market include Ganaxolone, SAGE-547 and others.
Table of Content
1. Key Insights
2. Executive Summary
3. Refractory status epilepticus Competitive Intelligence Analysis
4. Refractory status epilepticus Market Overview at a Glance
5. Refractory status epilepticus Disease Background and Overview
6. Refractory status epilepticus Patient Journey
7. Refractory status epilepticus Epidemiology and Patient Population
8. Refractory status epilepticus Treatment Algorithm, Current Treatment, and Medical Practices
9. Refractory status epilepticus Unmet Needs
10. Key Endpoints of Refractory status epilepticus Treatment
11. Refractory status epilepticus Marketed Products
12. Refractory status epilepticus Emerging Therapies
13. Refractory status epilepticus Seven Major Market Analysis
14. Attribute Analysis
15. Refractory status epilepticus Market Outlook (7 major markets)
16. Refractory status epilepticus Access and Reimbursement Overview
17. KOL Views on the Refractory status epilepticus Market.
18. Refractory status epilepticus Market Drivers
19. Refractory status epilepticus Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Refractory Status Epilepticus (RSE) Epidemiology Forecast to 2030
DelveInsight’s Refractory Status Epilepticus (RSE) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Refractory Status Epilepticus (RSE) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States